Akira Toyama

Akira Toyama

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
KYKensuke Yoshida
Kensuke Yoshida
YKYasumitsu Kodama
Yasumitsu Kodama
ANAtsushi Nishikawa
Atsushi Nishikawa
ASAndrea Rei Estacio Salazar
Andrea Rei Estacio Salazar
ATAkira Toyama
Akira Toyama
RTRitsuo Takagi
Ritsuo Takagi
According to the guidelines, the dosage for mandibular wisdom tooth extraction (MWTE) varies within the administration period. There is a 24-fold difference between the minimum and maximum doses. If an appropriate antimicrobial can be administered without increasing incidence of surgical site infection (SSI), it may lead to a global action plan on antimicrobial resistance (AMR). Therefore, we prospectively surveyed incidence of SSI post-operatively and use of oral antibiotics (OA) for MWTE. Subjects were patients who underwent MWTE in our dental outpatient clinic from May 2019 to April 2020. Two groups were formed depending on type of administration period they received: 24 h and 48 h after surgery. The following information was collected: (1) patient factors (age, gender, body mass index, presence/absence of preoperative medication, diagnosis, impacted wisdom tooth status; (2) surgical factors (operative time, presence/absence of closure, presence/absence of hemostat, doctor career, type and frequency of painkiller); (3) relationship between administration period of OA and SSI occurrence; and (4) details of SSI. Three hundred forty subjects were analyzed, all of which used amoxicillin. There were 106 cases in 24 h group and 234 cases in 48 h group. The total incidence of SSI was 1.1% (4/340 cases), with 0.9% (1/106 cases) in 24 h group and 1.3% (3/234 cases) in 48 h group; there was no difference between the two groups. Our study suggests that amoxicillin (250 mg/dose every 8 h x 3 doses beginning 1 h before surgery) might be sufficient in preventing SSI in Japanese dental patients without SSI risk factors.

1 January 2008 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
KSKentaro Sugiyama
Kentaro Sugiyama
KIKazuya Isogai
Kazuya Isogai
ATAkira Toyama
Akira Toyama
HSHiroshi Satoh
Hiroshi Satoh
KSKazuhide Saito
Kazuhide Saito
THToshihiko Hirano
Toshihiko Hirano
The lymphocyte immunosuppressant-sensitivity test (LIST) has been reported extensively as being able to estimate the pharmacological efficacy of immunosuppressive drugs in individual patients. This study measured the IC50 values for 6 drugs, cyclosporine, tacrolimus, methylprednisolone, 6-mercaptopurine, mycophenolic acid, and mizoribine, against mitogen-induced proliferation of peripheral-blood lymphocytes in 29 renal transplant recipients. We also examined relationship between the IC50 values and 4 factors; age, duration of dialysis, percentage of lymphocytes in total white blood cells, and blastogenesis stimulation index by mitogen. There were no significant correlations between the IC50 values and these factors, except that the tacrolimus IC50 value was correlated weakly with the stimulation index (p<0.05, r=−0.429). It was concluded that the pharmacological efficacy of immunosuppressive drugs cannot be inferred from the patient characteristics or their laboratory data. LIST is an effective method to elucidate the pharmacodynamic properties of immunosuppressive agents in individual renal transplant recipients without being influenced by the recipient clinical data.

1 October 2013 in Cell Medicine
Verified
Journal Article
Open access
HSHiroyasu Sasahara
Hiroyasu Sasahara
KSKentaro Sugiyama
Kentaro Sugiyama
MTMahoto Tsukaguchi
Mahoto Tsukaguchi
KIKazuya Isogai
Kazuya Isogai
ATAkira Toyama
Akira Toyama
THToshihiko Hirano
Toshihiko Hirano
The lymphocyte immunosuppressant sensitivity test (LIST) using patient peripheral lymphocytes can predict the therapeutic efficacy of immunosuppressive drugs used in renal transplantation. We have evaluated the pharmacological efficacy of drugs by using the LIST with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, which measures the cellular mitochondrial activity. The LIST with the MTT assay requires a relatively large amount of blood. As such, we developed a new assay for examining drug sensitivity with a CellTiter-Glo assay, which measures the amount of cellular ATP to help increase the assay's sensitivity and reduce the amount of blood needed. Renal transplant recipients generally receive either cyclosporine or tacrolimus, in addition to mycophenolate mofetil and methylprednisolone, as an immunosuppressive therapy to prevent acute rejection. We evaluated the pharmacological efficacy of these immunosuppressive agents with both the MTT and CellTiter-Glo assays using the peripheral blood mononuclear cells of 21 healthy volunteers. Furthermore, we also examined the relationship between these immunosuppressive agents' pharmacological efficacy and the results of the MTT and CellTiter-Glo assays. The IC50 values for cyclosporine, tacrolimus, mycophenolic acid, and methylprednisolone were significantly correlated between the MTT and CellTiter-Glo assays. The amount of blood cells required for LIST with the CellTiter-Glo assay was able to be reduced to 25% of the amount required for the previously established LIST with the MTT assay procedure. We concluded from these observations that the LIST with the CellTiter-Glo assay should be used instead of the MTT assay for carrying out individualized immunosuppressive therapy in renal transplantation patients.

14 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YSYUKI SAKAI
YUKI SAKAI
KKKouji Katsura
Kouji Katsura
MKMasaaki Kotake
Masaaki Kotake
ATAkira Toyama
Akira Toyama
Objectives: The aim of this study was to investigate the incidence and severity of oral adverse events in outpatients receiving cancer drug therapy and the need for oral management by medical professionals. Methods: A questionnaire-based survey was conducted among patients who received cancer drug therapy at our hospital between 1 and 30 September 2022. The incidence and severity of oral adverse events and the need for intervention by medical professionals were investigated. The risk factors for these events were also analyzed. Results: Of the 216 patients who answered the questionnaire, 127 (58.8%) experienced oral adverse events such as dysgeusia, oral mucositis, and xerostomia. Of the patients who experienced oral adverse events, 53.5% expressed that they wanted to improve their condition, 34.6% expressed that the adverse events affected their quality of life, and 26.8% wanted dental intervention. Thirty-two patients (25.2%) reported that the symptoms of these oral events were as severe as or more severe than those of other adverse events. The incidence of adverse oral events was significantly higher in patients treated with 5FU- and taxane-based regimens than in patients treated with other regimens. Conclusions: Our results suggest that cancer drug therapy, and the frequency and severity of oral adverse events, have a significant impact on the outpatients’ quality of life. More than a quarter of outpatients receiving cancer drug therapy wanted oral management through dental interventions. In particular, patients receiving 5FU-, taxane-, and anthracycline-based regimens may require oral management by medical professionals.

9 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YSYUKI SAKAI
YUKI SAKAI
KKKouji Katsura
Kouji Katsura
MKMasaaki Kotake
Masaaki Kotake
ATAkira Toyama
Akira Toyama
Objectives: The aim of this study was to investigate the incidence and severity of oral adverse events in outpatients receiving cancer drug therapy and the need for intervention by dental professionals. Methods: A questionnaire-based survey was conducted among patients who received cancer drug therapy at our hospital between September 1 and 30, 2022. The incidence and severity of oral adverse events and the need for intervention by dental professionals were investigated. The risk factors for these events were also analyzed. Results: Of the 216 patients who answered the questionnaire, 127 (58.8%) experienced oral adverse events such as dysgeusia, oral mucositis, and xerostomia. Of the patients who experienced oral adverse events, 53.5% showed that they wanted to improve their condition, 34.6% showed that the adverse events caused problems in their daily lives, and 26.8% wanted dental intervention. Thirty-two patients (25.2%) reported that the symptoms of these oral events were as severe as or more severe than those of other adverse events. The incidence of adverse oral events was significantly higher in patients treated with 5FU- and taxane-based regimens than in patients treated with other regimens. Conclusions: Our results suggest that oral adverse events have a significant impact on outpatients receiving cancer drug therapy. More than a quarter of outpatients receiving cancer drug therapy wanted oral management through dental interventions. In particular, patients receiving 5FU-, taxane-, and anthracycline-based regimens may require oral management by dental professionals.

1 October 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
MKMasaaki Kotake
Masaaki Kotake
YSYUKI SAKAI
YUKI SAKAI
SWSatoshi Watanabe
Satoshi Watanabe
TKToshiaki Kikuchi
Toshiaki Kikuchi
ATAkira Toyama
Akira Toyama
Background: The phase III PACIFIC trial demonstrated that one year of durvalumab maintenance therapy after concurrent chemoradiotherapy (CCRT) significantly improved overall survival (OS) in unresectable stage III non-small cell lung cancer (NSCLC), reducing the risk of death by 32% compared with observation. Durvalumab therapy administered for up to 12 months is currently the standard of care for patients with locally advanced NSCLC. This study aimed to identify the factors influencing the completion of durvalumab therapy. Methods: This retrospective study analyzed patients who initiated durvalumab therapy for unresectable NSCLC at Niigata University Medical and Dental Hospital between August 2018 and December 2022. Patients who discontinued the treatment for reasons unrelated to disease progression or adverse events were excluded. The patients were divided into durvalumab completion and non-completion groups, and the clinical factors influencing durvalumab completion were analyzed. Results: Among the 65 enrolled patients, 46.2% completed one year of durvalumab maintenance therapy. The completion rate was significantly lower in patients who received low-dose carboplatin as part of CCRT (20% vs. 54%, P=0.04), and higher in patients with adenocarcinoma (P=0.03). Older patients were more frequently treated with low-dose carboplatin CCRT (median age: 78 vs. 66 years, P<0.001). Patients receiving low-dose carboplatin had a significantly shorter time to treatment failure (median: 3.8 months vs. not reached, P=0.002) and tended to have a shorter OS (median: 47 months vs. not reached, P=0.06). Conclusions: Low-dose carboplatin CCRT is associated with lower durvalumab completion rates and worse outcomes, particularly in older patients. Alternative CCRT regimens may warrant consideration, particularly for older patients who are less likely to complete durvalumab maintenance.